Earlier this morning AroCell published their Q4 report. Though sales are still low, we emphasize that this is not what investors should focus on at this time. Instead, clinical studies, recruitment of key-personnel, strengthening of distribution partners and improved ownership structure are important parameters. These processes lay the ground for a well-prepared commercialization in the US, once the FDA has approved TK 210 ELISA.